NO20045236L - Fusjoner av cytokiner og tumor-targeting proteiner - Google Patents
Fusjoner av cytokiner og tumor-targeting proteinerInfo
- Publication number
- NO20045236L NO20045236L NO20045236A NO20045236A NO20045236L NO 20045236 L NO20045236 L NO 20045236L NO 20045236 A NO20045236 A NO 20045236A NO 20045236 A NO20045236 A NO 20045236A NO 20045236 L NO20045236 L NO 20045236L
- Authority
- NO
- Norway
- Prior art keywords
- cytokine
- tumor
- fusions
- cytokines
- ttm
- Prior art date
Links
- 108090000695 Cytokines Proteins 0.000 title abstract 6
- 102000004127 Cytokines Human genes 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000004927 fusion Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract 2
- 102100037850 Interferon gamma Human genes 0.000 abstract 2
- 108010074328 Interferon-gamma Proteins 0.000 abstract 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical group OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
- 102000016359 Fibronectins Human genes 0.000 abstract 1
- 108010067306 Fibronectins Proteins 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 102000000588 Interleukin-2 Human genes 0.000 abstract 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 abstract 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 abstract 1
- 102000007238 Transferrin Receptors Human genes 0.000 abstract 1
- 108010033576 Transferrin Receptors Proteins 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 101150047061 tag-72 gene Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0209893.7A GB0209893D0 (en) | 2002-04-30 | 2002-04-30 | Conjugate |
| PCT/IB2003/002515 WO2003092737A1 (en) | 2002-04-30 | 2003-04-30 | Fusions of cytokines and tumor targeting proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20045236L true NO20045236L (no) | 2005-01-31 |
Family
ID=9935814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20045236A NO20045236L (no) | 2002-04-30 | 2004-11-29 | Fusjoner av cytokiner og tumor-targeting proteiner |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20050074426A1 (ru) |
| EP (1) | EP1499362A1 (ru) |
| JP (1) | JP2005525115A (ru) |
| KR (1) | KR20050003400A (ru) |
| CN (2) | CN100457189C (ru) |
| AU (1) | AU2003236969A1 (ru) |
| CA (1) | CA2484425A1 (ru) |
| EA (2) | EA009955B1 (ru) |
| GB (1) | GB0209893D0 (ru) |
| IL (1) | IL164897A0 (ru) |
| NO (1) | NO20045236L (ru) |
| WO (1) | WO2003092737A1 (ru) |
| ZA (1) | ZA200408768B (ru) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1289565B1 (en) | 2000-06-02 | 2015-04-22 | Bracco Suisse SA | Compounds for targeting endothelial cells |
| US8263739B2 (en) | 2000-06-02 | 2012-09-11 | Bracco Suisse Sa | Compounds for targeting endothelial cells, compositions containing the same and methods for their use |
| WO2005094383A2 (en) * | 2004-03-31 | 2005-10-13 | Buck Institute | Hunter-killer peptides and methods of use |
| KR20070102684A (ko) | 2004-12-23 | 2007-10-19 | 몰메드 에스피에이 | 접합 생성물 |
| CA2602946A1 (en) * | 2005-03-22 | 2006-09-28 | Medstar Health, Inc. | Delivery systems and methods for diagnosing and treating cardiovascular diseases |
| CN1862258B (zh) | 2005-05-12 | 2012-05-30 | 清华大学 | 核仁素辅助的癌症诊断与治疗方法 |
| CA2608474C (en) | 2005-05-17 | 2019-11-12 | University Of Connecticut | Compositions and methods for immunomodulation in an organism |
| GB0708864D0 (en) * | 2007-05-08 | 2007-06-13 | Molmed Spa | Cytokine Conjugate |
| NO2631248T3 (ru) * | 2007-06-15 | 2018-04-14 | ||
| WO2009002562A2 (en) * | 2007-06-27 | 2008-12-31 | Marine Polymer Technologies, Inc. | Complexes of il-15 and il-15ralpha and uses thereof |
| GB0803076D0 (en) * | 2008-02-20 | 2008-03-26 | Univ Ghent | Mucosal Membrane Receptor and uses thereof |
| AU2008201871A1 (en) * | 2008-04-16 | 2009-11-26 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Inhibition of angiogenesis and tumor metastasis |
| US20110263512A1 (en) * | 2008-05-13 | 2011-10-27 | Molmed S.P.A | Conjugates for the treatment of mesothelioma |
| WO2011001276A1 (en) * | 2009-06-30 | 2011-01-06 | Philogen S.P.A. | Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer |
| US8822193B2 (en) | 2010-02-25 | 2014-09-02 | Marrone Bio Innovations, Inc. | Isolated bacterial strain of the genus Burkholderia and pesticidal metabolites therefrom |
| US9526251B2 (en) | 2010-02-25 | 2016-12-27 | Marrone Bio Innovations, Inc. | Use of Burkholderia formulations, compositions and compounds to modulate crop yield and/or corn rootworm infestation |
| CN102260352B (zh) * | 2010-05-28 | 2013-11-20 | 山东先声麦得津生物制药有限公司 | 靶向性白细胞介素融合蛋白及其制备方法与应用 |
| US9498499B2 (en) | 2012-04-19 | 2016-11-22 | The Board Of Trustees Of The Leland Stanford Junior University | Imaging-aided gene therapy using mesenchymal stem cells as target-delivery vehicle |
| US9119401B2 (en) | 2012-10-19 | 2015-09-01 | Marrone Bio Innovations, Inc. | Plant glutamine synthetase inhibitors and methods for their identification |
| CN104177500B (zh) * | 2013-05-24 | 2018-05-25 | 江苏靶标生物医药研究所有限公司 | 一种肿瘤坏死因子相关凋亡配体融合蛋白及其制法和用途 |
| ES2686668T3 (es) | 2013-07-19 | 2018-10-19 | Vib Vzw | Miembros de la familia TNF modificados dirigidos |
| US10400037B2 (en) | 2014-09-30 | 2019-09-03 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Binding molecules, especially antibodies, binding to L1CAM (CD171) |
| GB201419184D0 (en) | 2014-10-28 | 2014-12-10 | Adc Biotechnology Ltd | Method of synthesising biomolecule-effector/reporter-conjugates using affinity resins |
| CN104403004B (zh) | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| CN112574316A (zh) * | 2015-07-02 | 2021-03-30 | 博际生物医药科技(杭州)有限公司 | 用于肿瘤靶向治疗的白细胞介素-15融合蛋白 |
| RU2722449C2 (ru) | 2015-08-11 | 2020-06-01 | Кохерент Байофарма | Полилигандные лекарственные конъюгаты и их применения |
| CN105218682B (zh) * | 2015-10-26 | 2019-05-07 | 杨晶 | 经il-12/cd62l融合蛋白改造的肿瘤治疗剂及其制法和用途 |
| AU2016343805A1 (en) * | 2015-10-30 | 2018-06-07 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
| CN105585637B (zh) * | 2015-12-23 | 2020-04-03 | 杨晶 | 基于il-12稳定膜表达的肿瘤治疗剂及其制法和用途 |
| CN105622759A (zh) * | 2016-01-04 | 2016-06-01 | 深圳精准医疗科技有限公司 | IL-12/CD107a融合蛋白增强CTL抗肿瘤效果的治疗剂及其制法和用途 |
| GB201602359D0 (en) * | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| KR102312222B1 (ko) | 2016-12-22 | 2021-10-12 | 우니베르시따 델리 스투디 만냐 그레챠 카탄차로 | Ｃｄ43의 독특한 시알로글리코실화된 암-연관 에피토프를 표적으로 하는 모노클로날 항체 |
| JP7246617B2 (ja) * | 2017-02-01 | 2023-03-28 | アクセルロン ファーマ インコーポレイテッド | 免疫活性の増加における使用のためのＴＧＦβおよびＡＣＴＲＩＩアンタゴニスト |
| CN109467607B (zh) * | 2017-12-28 | 2020-10-30 | 北京泽勤生物医药有限公司 | 一种靶向肿瘤的酸性敏感融合肽及其应用 |
| CN108314741B (zh) * | 2018-03-22 | 2021-08-03 | 中国人民解放军第四军医大学 | 一种肿瘤血管靶向抗癌肽nkl-dota及其制备方法 |
| EP3794024B1 (en) * | 2018-05-14 | 2023-05-10 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| AU2019291955A1 (en) * | 2018-06-29 | 2021-02-18 | Platelet Biogenesis, Inc. | Compositions for drug delivery and methods of use thereof |
| CN108864251B (zh) * | 2018-06-30 | 2022-06-14 | 大连理工大学 | 一类氨肽酶n激活的药物前体化合物及其制备方法和应用 |
| CN117683140A (zh) * | 2022-09-09 | 2024-03-12 | 北京昌平实验室 | 肿瘤靶向的以白介素2为活性成分的融合蛋白型药物前体 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4578079A (en) * | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
| DE3423234A1 (de) * | 1984-06-23 | 1986-02-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
| US4650674A (en) * | 1984-07-05 | 1987-03-17 | Genentech, Inc. | Synergistic cytotoxic composition |
| US4879237A (en) * | 1985-05-24 | 1989-11-07 | La Jolla Cancer Research Foundation | Use of peptides in control of cell attachment and detachment |
| US4988621A (en) * | 1985-05-24 | 1991-01-29 | La Jolla Cancer Research Foundation | Peptides in cell detachment and aggregation |
| US5547936A (en) * | 1985-06-17 | 1996-08-20 | La Jolla Cancer Research Foundation | Inhibition of cell migration with synthetic peptides |
| US4935233A (en) * | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| DE3716513A1 (de) * | 1987-05-16 | 1988-11-24 | Basf Ag | Proteine mit tnf-wirkung |
| US5214131A (en) * | 1988-05-06 | 1993-05-25 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, modified peptides and production thereof |
| US5091176A (en) * | 1988-11-02 | 1992-02-25 | W. R. Grace & Co.-Conn. | Polymer-modified peptide drugs having enhanced biological and pharmacological activities |
| JPH04506061A (ja) * | 1989-03-15 | 1992-10-22 | タイコシンスキー，マーク エル． | Ｃｄ８に基づく製剤 |
| US5120829A (en) * | 1989-03-20 | 1992-06-09 | La Jolla Cancer Research Foundation | Hydrophobic attachment site for adhesion peptides |
| US5498694A (en) * | 1989-05-25 | 1996-03-12 | La Jolla Cancer Research Foundation | Peptides of the cytoplasmic domain of integrin |
| US5169930A (en) * | 1990-01-05 | 1992-12-08 | La Jolla Cancer Research Foundation | Fibronectin receptor |
| JPH04218000A (ja) * | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
| US5672585A (en) * | 1990-04-06 | 1997-09-30 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
| US5612311A (en) * | 1990-04-06 | 1997-03-18 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
| US5648330A (en) * | 1990-04-06 | 1997-07-15 | La Jolla Cancer Research Foundation | Method and composition for treating vascular graft occlusion |
| US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
| US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5811512A (en) * | 1991-08-22 | 1998-09-22 | The Trustees Of The University Of Pennsylvania | Non-peptide peptidomimetics and related cyclic hexapeptides |
| US5258517A (en) * | 1992-08-06 | 1993-11-02 | Sepracor, Inc. | Method of preparing optically pure precursors of paroxetine |
| US5536814A (en) * | 1993-09-27 | 1996-07-16 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| US5580853A (en) * | 1994-03-22 | 1996-12-03 | New England Deaconess Hospital | Modified polypeptides with increased biological activity |
| US5888814A (en) * | 1994-06-06 | 1999-03-30 | Chiron Corporation | Recombinant host cells encoding TNF proteins |
| US5811388A (en) * | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
| US5891418A (en) * | 1995-06-07 | 1999-04-06 | Rhomed Incorporated | Peptide-metal ion pharmaceutical constructs and applications |
| US6576239B1 (en) * | 1996-09-10 | 2003-06-10 | The Burnham Institute | Angiogenic homing molecules and conjugates derived therefrom |
| US6759509B1 (en) * | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
| US6180084B1 (en) * | 1998-08-25 | 2001-01-30 | The Burnham Institute | NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same |
| CN1239675A (zh) * | 1998-06-23 | 1999-12-29 | 金斗植 | 抗肿瘤试剂 |
| IT1317835B1 (it) * | 2000-02-15 | 2003-07-15 | San Raffaele Centro Fond | Citochine modificate per uso nella terapia del cancro. |
| US7309694B2 (en) * | 2000-02-15 | 2007-12-18 | Fondazione Centro San Raffaele Del Monte Tabor | Modified cytokines for use in cancer therapy |
| US7109303B2 (en) * | 2000-02-15 | 2006-09-19 | Fondazione Centro San Raffaele Del Monte Tabor | Modified cytokines for use in cancer therapy |
| PT1257297E (pt) * | 2000-02-24 | 2006-12-29 | Philogen Spa | Composições e método para tratamento da angiogénese em lesões patológicas |
| AU2001274894A1 (en) * | 2000-05-22 | 2001-12-03 | Pharmacia And Upjohn Company | Novel matrix metalloproteinases |
| CA2414650A1 (en) * | 2000-06-30 | 2002-01-10 | Board Of Regents, The University Of Texas System | Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery |
| US20030077818A1 (en) * | 2001-03-08 | 2003-04-24 | Dickerson Erin B. | Compositions and methods for targeting interleukin-12 to malignant endothelium |
| US20040110933A1 (en) * | 2002-09-13 | 2004-06-10 | Dyax Corporation | CD44-binding ligands |
-
2002
- 2002-04-30 GB GBGB0209893.7A patent/GB0209893D0/en not_active Ceased
-
2003
- 2003-04-30 EP EP03735883A patent/EP1499362A1/en not_active Withdrawn
- 2003-04-30 US US10/492,144 patent/US20050074426A1/en not_active Abandoned
- 2003-04-30 CN CNB038152037A patent/CN100457189C/zh not_active Expired - Fee Related
- 2003-04-30 AU AU2003236969A patent/AU2003236969A1/en not_active Abandoned
- 2003-04-30 CN CNA2008101868374A patent/CN101433722A/zh active Pending
- 2003-04-30 JP JP2004500920A patent/JP2005525115A/ja active Pending
- 2003-04-30 EA EA200401447A patent/EA009955B1/ru not_active IP Right Cessation
- 2003-04-30 WO PCT/IB2003/002515 patent/WO2003092737A1/en active Application Filing
- 2003-04-30 CA CA002484425A patent/CA2484425A1/en not_active Abandoned
- 2003-04-30 EA EA200800386A patent/EA200800386A1/ru unknown
- 2003-04-30 KR KR10-2004-7017535A patent/KR20050003400A/ko not_active Application Discontinuation
-
2004
- 2004-10-28 IL IL16489704A patent/IL164897A0/xx unknown
- 2004-10-29 ZA ZA200408768A patent/ZA200408768B/en unknown
- 2004-11-29 NO NO20045236A patent/NO20045236L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1665543A (zh) | 2005-09-07 |
| WO2003092737A1 (en) | 2003-11-13 |
| EA200401447A1 (ru) | 2005-08-25 |
| ZA200408768B (en) | 2007-03-28 |
| JP2005525115A (ja) | 2005-08-25 |
| EP1499362A1 (en) | 2005-01-26 |
| KR20050003400A (ko) | 2005-01-10 |
| CN101433722A (zh) | 2009-05-20 |
| IL164897A0 (en) | 2005-12-18 |
| US20050074426A1 (en) | 2005-04-07 |
| CN100457189C (zh) | 2009-02-04 |
| EA200800386A1 (ru) | 2008-10-30 |
| EA009955B1 (ru) | 2008-04-28 |
| GB0209893D0 (en) | 2002-06-05 |
| AU2003236969A1 (en) | 2003-11-17 |
| CA2484425A1 (en) | 2003-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20045236L (no) | Fusjoner av cytokiner og tumor-targeting proteiner | |
| Onishi et al. | An assessment of the immunological environment based on intratumoral cytokine production in renal cell carcinoma | |
| IS6322A (is) | Viðtaki APRIL (BCMA) og notkun hans | |
| PT857068E (pt) | Imunoterapia do cancro e doencas infecciosas utilizando celulas que apresentam antigenios sensibilizadas com complexos de proteina de choque termico-antigenio | |
| Brown et al. | T cell activation by Theileria annulata-infected macrophages correlates with cytokine production | |
| NO963018L (no) | CTLA4-mutantmolekyler og anvendelser derav | |
| SE8202012L (sv) | Humaninterferon-beslektade peptider, antigener, antikroppar och forfarande for framstellning derav | |
| FI893702A0 (fi) | Foerfarande foer mikrobiologisk framstaellning av humant serumalbumin och andra heterologa proteiner ur jaest. | |
| ATE217795T1 (de) | Saponin-antigen-konjugate und ihre verwendung | |
| DE69943170D1 (de) | Immunologische Zusammensetzung und Impfstoffe, die einen auf N-Formyl-Methionyl Peptide bestehenden Adjuvans enthalten | |
| Salgado et al. | Interleukin‐dependent modulation of HLA‐DR expression on CD4 and CD8 activated T cells | |
| DE69504955T2 (de) | Immunstimulierende monoklonale antikörper | |
| NZ332413A (en) | Use of interleukin-10 and an antigen or an CD-3 antibody to inhibit an antigen specific immune response | |
| FI852683A0 (fi) | Immunisk motverkan foer tumoerer och virus. | |
| DE69023061T2 (de) | Pufferverstärker mit niedrigem Ausgangswiderstand. | |
| ATE75053T1 (de) | Immunotest fuer biologisch wirksames menschliches interferon-gamma. | |
| IS6156A (is) | Samsettar ónæmisglæðablöndur | |
| Elsässer-Beile et al. | Impaired cytokine production in whole blood cell cultures of patients with urological carcinomas | |
| Ripepe et al. | Air-wave phases in strombolian explosion quake seismograms: a possible indicator for the magma level? | |
| FI862802A (fi) | Histaminderivat, immmunogenkonjugater och mot dessa producerade antikroppar. | |
| ES8500456A1 (es) | Procedimiento de inmunoanalisis para determinar procainamida o n-acetilprocainamida | |
| MY100476A (en) | Supported viral antigen and preparation and use thereof | |
| Dao et al. | Interleukin-2 production by T cells: A study of the immunoregulatory actions of interferon-α, interferon-γ, and tumor necrosis factor-α in phenotypically different T cell clones | |
| Hagihara et al. | The changes of serum soluble HLA-class I and CD8 concentrations during interferon treatment of chronic hepatitis C patients | |
| Ellingsworth | CHARACTERIZATION OF RHESUS MONKEY T-LYMPHOCYTE SUBPOPULATIONS AND SOME BIOCHEMICAL PROPERTIES OF A T-LYMPHOCYTE PRODUCED IMMUNOSUPPRESSIVE LYMPHOKINE. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |